Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17772020 | 0.93 | PDE4A (0.86) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL7700632 | 0.93 | PDE4A (0.86) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL30869220 | 0.90 | PDE4A (0.81) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL7702419 | 0.90 | PDE4A (0.81) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL14947100 | 0.89 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL3304195 | 0.87 | PDE4A (0.77) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL14936339 | 0.87 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL1697754 | 0.85 | PDE4A (1.00) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL1697755 | 0.83 | PDE4A (0.81) | PDE4APDE4DPDE4BPDE3BPDE3A | |
| SCHEMBL7698433 | 0.83 | PDE4A (0.70) | PDE4APDE4DPDE4BPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070091-A1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2016-09-21 | — | — | EP | claimed |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-05-16 | — | — | US | claimed |
| EP-3070091-B1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2019-04-17 | — | — | EP | disclosed |
| EP-3070091-B1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2019-04-17 | — | — | EP | disclosed |
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| US-9637499-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2017-05-02 | — | — | US | disclosed |
| EP-3070091-A1 | BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2016-09-21 | — | — | EP | disclosed |
| EP-2585469-B1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-05-25 | — | — | EP | disclosed |
| US-9273064-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-9273064-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2016-03-01 | — | — | US | disclosed |
| US-20150111915-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2015-04-23 | — | — | US | disclosed |
| US-20150111915-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2015-04-23 | — | — | US | disclosed |
| US-20150111915-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2015-04-23 | — | — | US | disclosed |
| US-8980905-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-03-17 | — | — | US | disclosed |
| US-8980905-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-03-17 | — | — | US | disclosed |
| US-8980905-B2 | Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-03-17 | — | — | US | disclosed |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-05-16 | — | — | US | disclosed |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-05-16 | — | — | US | disclosed |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111915-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE4A, PDE2A | PDE4A 2/4885PDE4D 16/4885PDE4B 6/4885 |
| US-20130123291-A1 | BENZODIOXOLE OR BENZODIOXEPINE HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE4A, PDE2A | PDE4A 2/4885PDE4D 18/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.